Is Bodycote (LSE:BOY) Reasonable After Its Approved Cash Deal?

Bodycote has delivered a strong share price run over the past few years, yet the real question for you today is how well that performance lines up with the cash the business is expected to generate. With a Discounted Cash Flow (DCF) intrinsic value estimate available, the focus turns to whether the current market valuation of Bodycote is consistent with those projected cash flows.

• Bodycote has returned 72.8% over the past 3 years, which puts real weight on whether the current valuation can be backed by future cash generation.
• The recommended cash acquisition by Vulcan Alpha Bidco Limited, expected to complete following remaining approvals by early 2027, may affect both the timing and visibility of Bodycote's future cash flows for shareholders.
• What if you looked at Bodycote through its earnings instead? See why Bodycote's 26.5x P/E tells a different valuation story.

The issue now is whether the cash flows implied by Bodycote's intrinsic value estimate are strong enough to justify where the stock trades today.

If you are weighing Bodycote's cash flow story against other opportunities, it can help to compare it with companies from our 11 high quality undervalued stocks.

Is Bodycote a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model looks at the cash Bodycote can return to shareholders over time. Latest twelve month free cash flow sits at about £63.8 million, and the model assumes that this stream grows from that base rather than shrinking, with projected annual free cash flow moving higher over the next decade in real terms.

Those rising cash flows, when discounted back, produce an intrinsic value that the DCF suggests is meaningfully above the current £9.15 share price. Because shareholders have already approved a recommended cash acquisition by Vulcan Alpha Bidco Limited, with completion targeted for early 2027, the agreed deal terms may explain why the market price does not fully track the DCF outcome for Bodycote even if the cash projections imply more value on a standalone basis. Find out what Bodycote could be worth using our Discounted Cash Flow (DCF) estimate.

The Bodycote Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Bodycote pick up where this valuation puzzle leaves you by spelling out which paths for growth, margins and earnings would need to unfold for the shares to end up worth materially more or less than today. Each scenario anchors a fair value estimate to a particular mix of potential catalysts and risks around Bodycote's business, so you can later compare the evolving facts with the storyline that looked most convincing at the outset.

Community views on Bodycote are split between those who see enough contract wins and cost programs to back the price, and those who think margin drag and bid quality still matter more.

Bull case: roughly fairly valued

"Major capacity expansions and upgrades in Bodycote’s U.S. aerospace and defense sites are now tied to renewed long term agreements with large Tier 1 customers…"

Discover why this Narrative puts Bodycote at roughly fairly valued.

Bear case: 14% overvalued

"Bid activity has become significant enough that one broker explicitly cited it when moving Bodycote from a Buy to a Hold rating in September 2026…"

Explore why this Narrative puts Bodycote at 14% overvalued.

Before moving on from Bodycote, there is one more lever to check

Prices and cash flows are only part of the picture for Bodycote. The people setting priorities and the way they are rewarded can tilt outcomes in ways the spreadsheet never shows. See who runs Bodycote and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com